Results 101 to 110 of about 65,998 (238)

Risk Factors for Cutaneous Immune‐Related Adverse Events in the Japanese Population: A Retrospective Single‐Center Cohort Study

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Immune checkpoint inhibitor (ICI)‐driven alterations in the immune system can induce immune‐related adverse events (irAEs). Cutaneous irAEs are notable for being the most common and for their early onset; however, the risk factors underlying their development and severity remain unclear. In this study, we retrospectively analyzed 1224 Japanese
Tomoya Watanabe   +4 more
wiley   +1 more source

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre‐Operative PD1 CheckpOint Blockade and Receptor Activator of NF‐κB Ligand (RANKL) Inhibition in Non‐Small Cell Lung Cancer (NSCLC)—A Phase 1B/2 Trial

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
Expanding on the growing evidence for neoadjuvant immunotherapy in resectable non‐small cell lung cancer, this study explored neoadjuvant nivolumab ± denosumab. Two of the 10 treated patients achieved a pathological complete response. CD8 T‐cell infiltration correlated with pathological response, warranting ongoing translational research to understand ...
Elizabeth Ahern   +11 more
wiley   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski   +6 more
wiley   +1 more source

Skin Abnormalities at Checkpoint Inhibitor Therapy Initiation Are Associated With Skin Rash Development in Oncology Patients

open access: yesAllergy, EarlyView.
Skin tape strip lipidomic analysis revealed preexisting skin barrier lipid abnormalities at day 0 that were further exacerbated after 6 weeks of CPI treatment. Significant changes in skin (but not plasma) proinflammatory cytokines were identified in future ircAE patients after 6 weeks of CPI immunotherapy.
Taras Lyubchenko   +9 more
wiley   +1 more source

Basophils in Immunity: Activation Pathways, Roles in Allergy and AllergoOncology and Application of the Basophil Activation Test

open access: yesAllergy, EarlyView.
ABSTRACT Basophils, the least abundant leukocytes, are increasingly recognised as potent immunomodulators. Upon activation, they rapidly release preformed granule‐associated mediators including histamine and lipid mediators such as LTC4, while cytokine production occurs over a longer timescale, contributing to downstream immune responses.
Jitesh Chauhan   +5 more
wiley   +1 more source

T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors

open access: yesAndrology, EarlyView.
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam   +7 more
wiley   +1 more source

What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta‐analysis of ocular immune‐related adverse events

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune‐related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI‐associated DED and to evaluate factors contributing to variability across studies.
Kai‐Yang Chen   +2 more
wiley   +1 more source

Response evaluation of neoadjuvant therapy in MIBC: clinical trial‐derived evidence to guide practice

open access: yesBJU International, EarlyView.
Objectives To review how response to neoadjuvant therapy (NAT) is assessed in clinical trials of muscle‐invasive bladder cancer (MIBC), and to determine whether trial‐derived evidence can inform response evaluation in contemporary practice. Subjects/Patients and Methods We searched PubMed, Embase and ClinicalTrials.gov through August 2025 for ...
Roberto Contieri   +9 more
wiley   +1 more source

Association Between Blood Transfusion and Survival Outcomes in Metastatic Cutaneous Melanoma Treated with Nivolumab. [PDF]

open access: yesCancer Manag Res
Coskun A   +8 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy